The financials
ADMA Biologics, Inc. by the numbers
ADMA Biologics, Inc. (ADMA) reported revenue of $114M in Q1 2026 (quarter ended Mar 31, 2026), down 0.3% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $45M (40% of revenue). For the full year FY2025, revenue was $510M (+20% year on year) and net income $147M. Its largest segment in Jun 2026 was ADMA Bio Manufacturing at $123M, 100% of the disclosed total, well ahead of Plasma Collection Centers at 0.0%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $114M | $115M | −0.3% |
| Gross profit | $81M | $61M | +32% |
| Operating income | $58M | $35M | +67% |
| Net income | $45M | $27M | +68% |
| Diluted EPS | $0.19 | $0.11 | +73% |
| Operating | Revenue | Share |
|---|---|---|
| ADMA Bio Manufacturing | $123M | 100% |
| Plasma Collection Centers | $30K | 0.0% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $123.3M (+8.7%)
ADMA Bio Manufacturing grew +1.1% year on year
Segment Latestquarter on quarteryear on year
- ADMA Bio Manufacturing$123.3M$123.3MQoQ +8.7%year on year +1.1%+8.7%+1.1%
- Plasma Collection Centers$30.0K$30.0KQoQ +15%year on year -+15%-